Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Key Stats

• Today's Range: $8.00 to $8.50
• 50-Day Range: $8.28 to $15.69
• 52-Week Range: $6.10 to $20.90
• Volume: 1.14 million shs
• Average Volume: 328,133 shs
• Market Capitalization: $370.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.89
• Consensus Rating: Buy

Y-mAbs Therapeutics Stock Analysis - MarketRank™

Y-mAbs Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 626th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Y-mAbs Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.66) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Y-mAbs Therapeutics is -15.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Y-mAbs Therapeutics is -15.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Y-mAbs Therapeutics has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.33% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Y-mAbs Therapeutics does not currently pay a dividend.

Dividend Growth

Y-mAbs Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.33% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.54

News Sentiment

Y-mAbs Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Y-mAbs Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for YMAB on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

YMAB Stock Analysis - Frequently Asked Questions

How have YMAB shares performed this year?

Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB shares have increased by 21.4% and is now trading at $8.28.
View the best growth stocks for 2024 here.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings data on Friday, November, 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The business had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 24.61% and a negative net margin of 28.22%.

When did Y-mAbs Therapeutics IPO?

Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' top institutional shareholders include State Street Corp (2.70%), Caligan Partners LP (2.67%), Geode Capital Management LLC (1.82%) and Charles Schwab Investment Management Inc. (0.63%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Vignesh Rajah and Joris Wilms.
View institutional ownership trends.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:YMAB
• CUSIP: N/A
• CIK: 1722964
• Web: www.ymabs.com
• Phone: (646) 885-8505
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.89
• High Stock Price Target: $26.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +152.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,430,000.00
• Net Margins: -28.22%
• Pretax Margin: -27.28%
• Return on Equity: -24.61%
• Return on Assets: -18.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.92
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $84.55 million
• Price / Sales: 4.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.32 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 44,789,000
• Free Float: 34,711,000
• Market Cap: $370.85 million
• Optionable: Optionable
• Beta: 0.61